Abstract
Mycoplasma pneumoniae is one of the widespread causes of community-acquired pneumonia (CAP). Over recent years, the widespread use of macrolides has led to the emergence of macrolide-resistant M.pneumoniae (MRMP) resulted from mutations at specific positions of domain V of the 23S rRNA gene. We collected 100 samples of throat swabs from patients with respiratory infections. After extraction of DNA from bacterial cell cultured in PPLO broth media using Roche kit (Germany), the PCR was performed on specific samples of M. pneumoniae using specific primers for 23S rRNA gene.Afterwards, for positive samples, minimum inhibitory concentration (MIC) was determined using the broth microdilution with Clarithromycin. Finally, the PCR product was sequenced to detect mutations related to macrolide resistance in domain V of 23S rRNA . According to the analysis of the sequenced PCR product of M. pneumoniae 23S rRNA gene using Clustalw2 online software, one of the samples were shown to have a mutation at A2431G and G2491A positions. The MIC measurement also revealed that all isolates were sensitive to Clarithromycin, and there was no macrolide resistance to Clarithromycin in all isolates. Sequence analysis of the 23S rRNA gene in M. pneumoniae , revealed no macrolide resistance of M. pneumoniae to Clarithromycin. Thus, the use of these antibiotics should be restricted to prevent the development of macrolide-resistant M. pneumoniae in Iran.
Highlights
Mycoplasma pneumoniae (M. pneumoniae) is one of the most leading causes of communityacquired pneumonia (CAP) [1,2,3]
Mycoplasma Pneumoniae is a major cause of community-acquired pneumonia [5]
Macrolide antibiotics are recommended as the first-line treatment for M. pneumoniae [1, 10]
Summary
Mycoplasma pneumoniae (M. pneumoniae) is one of the most leading causes of communityacquired pneumonia (CAP) [1,2,3]. The duration of treatment of infections with ML-resistant M. pneumoniae (MRMP) is longer compared to treatment-sensitive infections [11,12]. It was first reported in Japan, and in other parts of the world, including the United States, Europe, East. The widespread use of macrolides has led to the emergence of macrolide-resistant M. pneumoniae (MRMP) resulted from mutations at specific positions of domain V of the 23S rRNA gene. Results: According to the analysis of the sequenced PCR product of M. pneumoniae 23S rRNA gene using Clustalw online software, one of the samples were shown to have a mutation at A2431G and G2491A positions. Conclusions: Sequence analysis of the 23S rRNA gene in M. pneumoniae, revealed no macrolide resistance of M. pneumoniae to Clarithromycin. The use of these antibiotics should be restricted to prevent the development of macrolide-resistant M. pneumoniae in Iran
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
